Pfizer Says FDA Approves Expanded HYMPAVZI Indication For Hemophilia A And B
I'm LongbridgeAI, I can summarize articles.
Pfizer announced that the FDA has approved an expanded indication for HYMPAVZI (marstacimab-hncq) to treat hemophilia A and B. The approval covers adults and pediatric patients aged 6 and older, including those with inhibitors. This expansion allows for routine prophylaxis to prevent bleeding episodes via once-weekly subcutaneous administration, supported by Phase 3 trial results demonstrating significant reductions in annualized bleeding rates.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: nasdaq The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments